GB0705245D0 - Stable biological products - Google Patents

Stable biological products

Info

Publication number
GB0705245D0
GB0705245D0 GBGB0705245.9A GB0705245A GB0705245D0 GB 0705245 D0 GB0705245 D0 GB 0705245D0 GB 0705245 A GB0705245 A GB 0705245A GB 0705245 D0 GB0705245 D0 GB 0705245D0
Authority
GB
United Kingdom
Prior art keywords
polyethyleneimine
viral particles
biological products
stable biological
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0705245.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stabilitech Ltd
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Priority to GBGB0705245.9A priority Critical patent/GB0705245D0/en
Publication of GB0705245D0 publication Critical patent/GB0705245D0/en
Priority to GB0915291A priority patent/GB2459611B/en
Priority to RU2009138344/10A priority patent/RU2009138344A/ru
Priority to US12/531,902 priority patent/US8313897B2/en
Priority to JP2009554082A priority patent/JP2010521961A/ja
Priority to BRPI0808960-4A priority patent/BRPI0808960A2/pt
Priority to AU2008228086A priority patent/AU2008228086A1/en
Priority to PCT/GB2008/000987 priority patent/WO2008114021A1/en
Priority to KR1020097021553A priority patent/KR20100015613A/ko
Priority to EP08718824A priority patent/EP2121898B8/en
Priority to CN200880008926A priority patent/CN101636486A/zh
Priority to CA002681182A priority patent/CA2681182A1/en
Priority to SI200830486T priority patent/SI2121898T1/sl
Priority to DK08718824.9T priority patent/DK2121898T3/da
Priority to PL08718824T priority patent/PL2121898T3/pl
Priority to HR20110814T priority patent/HRP20110814T1/hr
Priority to AT08718824T priority patent/ATE525455T1/de
Priority to ES08718824T priority patent/ES2370675T3/es
Priority to IL200671A priority patent/IL200671A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GBGB0705245.9A 2007-03-19 2007-03-19 Stable biological products Ceased GB0705245D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB0705245.9A GB0705245D0 (en) 2007-03-19 2007-03-19 Stable biological products
ES08718824T ES2370675T3 (es) 2007-03-19 2008-03-19 Procedimiento para proteger partículas virales.
KR1020097021553A KR20100015613A (ko) 2007-03-19 2008-03-19 바이러스 입자 보전 방법
CN200880008926A CN101636486A (zh) 2007-03-19 2008-03-19 保存病毒颗粒的方法
US12/531,902 US8313897B2 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
JP2009554082A JP2010521961A (ja) 2007-03-19 2008-03-19 ウイルス粒子を保存するための方法
BRPI0808960-4A BRPI0808960A2 (pt) 2007-03-19 2008-03-19 Método para preservar partículas virais, excipiente para a preservação de partículas virais, uso de um excipiente, kit, método para preparar uma vacina, e, pó seco.
AU2008228086A AU2008228086A1 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
PCT/GB2008/000987 WO2008114021A1 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
GB0915291A GB2459611B (en) 2007-03-19 2008-03-19 Method for preserving viral particles
EP08718824A EP2121898B8 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
RU2009138344/10A RU2009138344A (ru) 2007-03-19 2008-03-19 Способ консервации вирусных частиц
CA002681182A CA2681182A1 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
SI200830486T SI2121898T1 (sl) 2007-03-19 2008-03-19 Postopek za ohranitev virusnih delcev
DK08718824.9T DK2121898T3 (da) 2007-03-19 2008-03-19 Fremgangsmåde til konservering af viruspartikler
PL08718824T PL2121898T3 (pl) 2007-03-19 2008-03-19 Sposób konserwowania cząstek wirusowych
HR20110814T HRP20110814T1 (hr) 2007-03-19 2008-03-19 Metoda konzerviranja čestica virusa
AT08718824T ATE525455T1 (de) 2007-03-19 2008-03-19 Verfahren zur konservierung von viruspartikeln
IL200671A IL200671A0 (en) 2007-03-19 2009-09-01 Method for preserving viral particles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0705245.9A GB0705245D0 (en) 2007-03-19 2007-03-19 Stable biological products

Publications (1)

Publication Number Publication Date
GB0705245D0 true GB0705245D0 (en) 2007-04-25

Family

ID=38008686

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0705245.9A Ceased GB0705245D0 (en) 2007-03-19 2007-03-19 Stable biological products
GB0915291A Expired - Fee Related GB2459611B (en) 2007-03-19 2008-03-19 Method for preserving viral particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0915291A Expired - Fee Related GB2459611B (en) 2007-03-19 2008-03-19 Method for preserving viral particles

Country Status (18)

Country Link
US (1) US8313897B2 (enExample)
EP (1) EP2121898B8 (enExample)
JP (1) JP2010521961A (enExample)
KR (1) KR20100015613A (enExample)
CN (1) CN101636486A (enExample)
AT (1) ATE525455T1 (enExample)
AU (1) AU2008228086A1 (enExample)
BR (1) BRPI0808960A2 (enExample)
CA (1) CA2681182A1 (enExample)
DK (1) DK2121898T3 (enExample)
ES (1) ES2370675T3 (enExample)
GB (2) GB0705245D0 (enExample)
HR (1) HRP20110814T1 (enExample)
IL (1) IL200671A0 (enExample)
PL (1) PL2121898T3 (enExample)
RU (1) RU2009138344A (enExample)
SI (1) SI2121898T1 (enExample)
WO (1) WO2008114021A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
AU2009295623A1 (en) 2008-09-24 2010-04-01 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
EP3266448B1 (en) 2009-03-27 2022-02-16 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
SG176253A1 (en) 2009-05-26 2011-12-29 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NZ601017A (en) * 2010-01-28 2014-07-25 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
JP5869553B2 (ja) * 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
CL2011001984A1 (es) 2010-08-13 2012-06-29 Advanced Bionutrition Corp Composicion seca estabilizadora para material biologico que comprende carbohidrato, proteinas hidrolizadas de animal o de planta y un componente de acido carboxilico; metodo de preparacion; y formulacion de entrega oral que comprende la composicion seca estabilizadora.
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
EP3328215B1 (en) 2015-07-29 2021-07-07 Advanced BioNutrition Corp. Stable dry probiotic compositions for special dietary uses
US10752876B2 (en) 2015-09-02 2020-08-25 Mcmaster University Enhanced thermal stability for adenoviral vectors through spray drying
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US11626228B2 (en) * 2016-12-22 2023-04-11 Rogers Corporation Multi-layer magneto-dielectric material
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JPWO2020066991A1 (ja) * 2018-09-28 2021-08-30 株式会社大塚製薬工場 アカルボース又はスタキオースを含む哺乳動物細胞保存用液
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR CANCER THERAPY
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
CN113613664B (zh) 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
CA3171097A1 (en) * 2020-04-14 2021-10-21 Federico Carlos Arejola Gaeta Products and methods for detection of viral nucleic acid
WO2022011099A1 (en) * 2020-07-08 2022-01-13 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
CA3207206A1 (en) 2021-02-01 2022-08-04 Lingfeng LIU Targeted protein degradation system and use thereof
WO2022246323A1 (en) * 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN113655057A (zh) * 2021-08-24 2021-11-16 威世药业（如皋）有限公司 一种检测冷冻干燥处理对痘苗病毒毒力影响的设备
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
ES2237551T3 (es) 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US20040110267A1 (en) * 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
WO2007042884A1 (en) * 2005-10-07 2007-04-19 Pfizer Products Inc. Vaccines and methods to treat canine influenza

Also Published As

Publication number Publication date
GB2459611B (en) 2011-02-16
RU2009138344A (ru) 2011-04-27
ES2370675T3 (es) 2011-12-21
SI2121898T1 (sl) 2012-02-29
IL200671A0 (en) 2011-08-01
WO2008114021A1 (en) 2008-09-25
US20100015177A1 (en) 2010-01-21
EP2121898B8 (en) 2012-02-15
DK2121898T3 (da) 2012-01-09
GB0915291D0 (en) 2009-10-07
US8313897B2 (en) 2012-11-20
BRPI0808960A2 (pt) 2014-08-26
JP2010521961A (ja) 2010-07-01
CN101636486A (zh) 2010-01-27
AU2008228086A1 (en) 2008-09-25
PL2121898T3 (pl) 2012-02-29
EP2121898B1 (en) 2011-09-21
HRP20110814T1 (hr) 2012-01-31
GB2459611A (en) 2009-11-04
ATE525455T1 (de) 2011-10-15
KR20100015613A (ko) 2010-02-12
CA2681182A1 (en) 2008-09-25
EP2121898A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
GB2459611B (en) Method for preserving viral particles
GB2479069A (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
WO2006070370A3 (en) Stem cells culture systems
WO2009118253A3 (en) Hair styling composition
DK1898721T3 (da) Fremgangsmåde til fremstilling af en vandig suspension og et pulverformigt præparat af et eller flere carotioider
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2006099258A8 (en) Tigecycline compositions and methods of preparation
WO2011022435A3 (en) Biocontrol microorganisms
CL2010001372A1 (es) Procedimiento para la produccion de frutooligosacaridos a partir de sacarosa que comprende contactar la sacarosa con una enzima no inmivilizada con actividad inulinasa y/o fructosil transferasa.
WO2006116622A3 (en) Novel methods and devices for evaluating poisons
AR052980A1 (es) Preparacion de dispersiones polimericas de etileno - acido acrilico neutralizadas y uso en medios de impresion para mejorar la adhesion de pigmento organico digital
WO2008125972A3 (en) Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
BRPI0923357A2 (pt) Métodos para acelerar o crescimento de raízes em uma planta, e para melhorar a absorção foliar de um composto biologicamente ativo por uma planta.
WO2005017098A3 (en) AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA
WO2007144508A3 (fr) Arn de transfert chimerique et son utilisation pour la production d'arn par une cellule
WO2011128682A3 (en) Device for preparing dilute disinfectant solution
WO2007120302A3 (en) Liquid crystalline substrates for culturing cells
WO2007047680A3 (en) Increasing the activity of radical s-adenosyl methionine (sam) enzymes
UA91057C2 (ru) Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
HK1159119B (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2008049583A3 (de) Verfahren zur selektiven lokalisierung von wirkstoffen an und in mitochondrien und entsprechende wirkstoffe
WO2009051016A1 (ja) シリコン量子ドット、及びそれを用いた生体物質標識剤

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)